{"id":"W2946957740","doi":"10.1016/j.clgc.2021.05.004","title":"Active Surveillance in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System","year":2021,"lang":"en","type":"article","venue":"Clinical Genitourinary Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université Laval; Centre Hospitalier de l’Université de Montréal; Princess Margaret Cancer Centre; University of Calgary; University of British Columbia; McMaster University; Sunnybrook Health Science Centre; University of Manitoba; Juravinski Cancer Centre; Queen Elizabeth II Health Sciences Centre; University of Alberta; CancerCare Manitoba; Ottawa Hospital; McGill University Health Centre; University of Ottawa","funders":"Genentech; Ipsen; Amgen Astellas Biopharma; Astellas Pharma; Merck Sharp and Dohme; Bristol-Myers Squibb Canada; Eisai; AbbVie; Exelixis; Sanofi; Roche; Karyopharm Therapeutics; Novartis; MedImmune; GlaxoSmithKline; Boehringer Ingelheim; Amgen; Pfizer; Bayer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Cohort; Hazard ratio; Renal cell carcinoma; Internal medicine; Kidney cancer; Systemic therapy; Cancer; Cohort study; Confidence interval; Oncology; Breast cancer","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005711153,0.000285526,0.00063616,0.00009624811,0.000172143,0.00005454481,0.0002044536,0.0001796377,0.0002015597],"category_scores_gemma":[0.0005013029,0.0002071379,0.0002489141,0.000477494,0.0001216292,0.0001803199,0.00008908648,0.0006990811,0.0001042873],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002035993,"about_ca_system_score_gemma":0.006457202,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.3236319,"about_ca_topic_score_gemma":0.2873658,"domain_scores_codex":[0.9968696,0.0005307439,0.001122925,0.0005176681,0.0004499689,0.0005090803],"domain_scores_gemma":[0.9971303,0.0006687613,0.000323811,0.000741254,0.0003983552,0.0007375275],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.005800596,0.0004420328,0.9018928,0.0004269143,0.0006267926,0.006588359,0.002640674,0.000965414,0.0004072262,0.00001846701,0.05803252,0.02215814],"study_design_scores_gemma":[0.006814561,0.0002291529,0.9587649,0.0002968046,0.0002445026,0.00004419073,0.0007705927,0.0005735082,0.003043876,0.000008560276,0.0289468,0.0002626312],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9775002,0.002561464,0.000003875392,0.007502024,0.001239381,0.0007067163,0.002350868,0.00003286507,0.008102578],"genre_scores_gemma":[0.993946,0.0004215873,0.0002249962,0.002809518,0.0008748687,0.0002299296,0.0007041855,0.00002756662,0.0007613815],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05687196,"threshold_uncertainty_score":0.9991753,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05802921157147152,"score_gpt":0.3275666794121709,"score_spread":0.2695374678406994,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}